Mouse Flt-3 Ligand ELISA Kit (DEIA2907)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
cell culture supernatants, serum, serum
Species Reactivity
Mouse
Intended Use
For the quantitative determination of mouse Flt-3 Ligand concentrations in cell culture supernates, mouse serum, and rat serum.
Contents of Kit
1. Mouse Flt-3 Ligand Microplate
2. Mouse Flt-3 Ligand Conjugate
3. Mouse Flt-3 Ligand Standard
4. Mouse Flt-3 Ligand Control
5. Assay Diluent
6. Calibrator Diluent
7. Wash Buffer Concentrate
8. Color Reagent A
9. Color Reagent B
10. Stop Solution
Storage
Store at 4°C for frequent use, at -20°C for infrequent use. Avoid multiple freeze-thaw cycles.
Return unused wells to the foil pouch containing the desiccant pack, reseal along entire edge of zip-seal. May be stored for up to 1 month at 2-8°C.
Precision
Intra-assay Precision:
3.7-4.9%

Inter-assay Precision:
5.1-7.5%
Sensitivity
5 pg/mL

Citations


Have you cited DEIA2907 in a publication? Let us know and earn a reward for your research.

Related Products


Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Promoter profiling and coexpression data analysis identifies 24 novel genes that are coregulated with AMPA receptor genes, GRIAs

GENOMICS

Authors: Chong, Allen; Zhang, Zhuo; Choi, Kwok Pui; Choudhary, Vidhu; Djamgoz, Mustafa B. A.; Zhang, Guanglan; Bajic, Vladimir B.

We identified a set of transcriptional elements that are conserved and overrepresented within the promoters of human, mouse, and rat GRIAs by comparing these promoters against a collection of 10,741 gene promoters. Cells regulate functional groups of genes by coordinating the transcriptional and/or posttranscriptional mRNA levels of interacting genes. As such, it is expected that functional groups of genes share the same transcriptional features within their promoters. We found 47 genes whose promoters contain the same combination of transcriptional elements that are overrepresented within the promoters of the GRIA gene family. Coexpressed genes may be transcriptionally coregulated, which in turn suggests that these genes may play complementary roles within a particular functional context. Using microarray expression data, we found 24 (of the 47) genes that share not only a similar promoter profile with GRIAs but also a well-correlated gene expression profile and, thus, we believe these to be coregulated with GRIAs. (c) 2006 Elsevier Inc. All rights reserved.

Sjogren Syndrome-associated lymphomas: an update on pathogenesis and management

BRITISH JOURNAL OF HAEMATOLOGY

Authors: Nocturne, Gaetane; Mariette, Xavier

Primary Sjogren Syndrome (pSS) is an autoimmune disease associated with an increased risk of lymphoma. Lymphomas complicating pSS are mostly low-grade B cell non-Hodgkin lymphomas, predominantly of marginal zone histological type. Mucosal localization is predominant, notably mucosa-associated lymphoid tissue lymphomas. Lymphomas often develop in organs where pSS is active, such as salivary glands. Germinal centre (GC)-like structures, high TNFSF13B (BAFF) and Flt3-ligand (FLT3LG) levels and genetic impairment of TNFAIP3 are new predictors of lymphoma development. These new findings allow a better understanding of the pathogenic mechanisms leading to lymphoma. We propose the following scenario: auto-immune B cells with rheumatoid factor (RF) activity are continuously stimulated by immune complexes containing antibodies against more specific auto-antigens, such as SSA/Ro, SSB/La or others. Germline abnormality of TNFAIP3 leads to a decreased control of the NF-kB pathway and thus promotes survival of B cells and oncogenic mutations especially in GC structure. Moreover, B cells are stimulated by a positive loop of activation induced by BAFF secretion. Thus, lymphomagenesis associated with pSS exemplifies the development of antigen-driven B-cell lymphoma. The control of disease activity by a well-targeted immunosuppressor is the primary objective of the management of the patient in order to repress chronic B cell stimulation.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket